KYTHERA (NASDAQ: KYTH) is a biopharmaceutical company that focuses on developing and commercializing high-demand medical aesthetics products. We target large-scale global opportunities to develop innovative drugs and medical devices to treat under-addressed aesthetic complaints. We look for market segments with both motivated patients and motivated physicians. Our longer-term strategy is to leverage our biotechnology and aesthetics experience to aggressively expand our product portfolio and pipeline.
Aug 18, 2015
KYTHERA(R) Biopharmaceuticals Submits Marketing Authorization Application in the European Union for ATX-101 as First-in-Class Treatment for the Reduction of Submental Fat
Aug 6, 2015
Jun 9, 2015 at 2:00 PM PT
May 7, 2015 at 1:30 PM PT